‘Ticking Time Bomb’; Jimmy Carter’s Lasting Impact on Cancer; Breast Cancer-CVD Link

Liver cells damaged by diet-driven metabolic dysfunction are like a “ticking time bomb” in the evolution of liver cancer, according to a study in Nature. (UC San Diego)

Viracta Therapeutics announced the closure of a phase II trial of its combination therapy of the histone deacetylase inhibitor nanatinostat and the antiviral agent valganciclovir for relapsed/refractory Epstein-Barr virus-positive lymphomas to “explore a broad range of strategic alternatives.”

Former President Jimmy Carter had a lasting impact on the development and awareness of cancer immunotherapy. (NBC News)

STAT reported on the waning reliance on stem cell transplants for hematologic malignancies.

An editorial cautioned about direct-to-consumer tests for cancer predisposition genes. (Oncotarget)

Clinical practice experience with pembrolizumab (Keytruda) for triple-negative breast cancer provided new insights into the use, benefits, and potential side effects of the treatment. (Cleveland Clinic)

A California oncologist agreed to pay $3 million to the U.S. Securities and Exchange Commission to settle allegations of insider trading related to the doctor’s research on a new cancer drug. (Mondaq)

A “speckle” of evidence may help explain why some patients respond to a treatment and others do not. (Cold Spring Harbor Laboratory)

Expected during the first half of 2025, data from 10 clinical studies could have an impact on cancer and other diseases. (Biopharma Dive)

Immuno-oncology and cancer therapeutics are projected to drive innovation in the drug-development pipeline for the next 5 years. (GlobalData)

Advanced or metastatic breast cancer, besides posing its own threat, might also signal undiagnosed cardiovascular disease. (University of Texas MD Anderson Cancer Center)